Skip to main content

Advertisement

SpringerLink
Log in

Hypersensitivity Reactions to Non-Beta Lactam Antibiotics

  • Drug Allergy (C Mayorga, Section Editor)
  • Published:
Current Treatment Options in Allergy Aims and scope Submit manuscript

Abstract

Purpose of Review

Hypersensitivity reactions (HRs) to non-beta lactam antibiotics (NBLAs) have increased over the last years. Although NBLAs with their broad spectrum are widely used to treat various infections, knowledge about HRs due to these drugs is limited when compared to beta-lactam antibiotics (BLAs). Therefore, we aimed to discuss the structures, subgroups of various NBLAs including fluoroquinolones, macrolides, sulfonamides, first-line anti-tuberculosis agents, 5-nitroimidazols, aminoglycosides, glycopeptides, clindamycin, and tetracyclines, and we also reviewed epidemiology, clinical characteristics, cross-reactivity, diagnostic methods, and management of related HRs.

Recent Findings

These agents can lead to occurrence of immediate and/or non-immediate HRs mediated by immunologic and/or non-immunologic mechanisms. There are no validated in vivo or in vitro tests for their diagnosis. Management strategy is similar to that of HRs due to BLAs which includes avoidance or desensitization.

Summary

In this article in vivo and in vitro diagnostic tests and management strategies for NBL HRs are discussed in detail to provide guidance for daily clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, et al. Drug hypersenstivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;2(2):363–71.

    Google Scholar 

  2. Sanchez-Borges M, Thong B, Blanca M, LFC E, Gonzalez-Diaz S, Greenberger PA, et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organization Journal. 2013;(6):18.

  3. Kuyucu S, Mori F, Atanaskovic-Markovic M, Caubet JC, Terreehorst I, Gomes E, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive reviw. Pediatric Allergy and Immunology. 2014;25:534–43.

    PubMed  Google Scholar 

  4. Van bambeke F, Michot JM, Van Elderej TPM. Quinolones in 2005: an update. Clin Microbiol Infect. 2005;(11):256–80.

  5. TDM P, Ziora ZM, MAT B. Quinolone antibiotics. Med. Chem. Commun. 2019;10:1719.

    Article  Google Scholar 

  6. EU MG, Samuel E, Boronea B, Dillard N, Milby MN, Lewis SJ. Quinolone allergy. Pharmacy. 2019;7:97.

    Article  Google Scholar 

  7. Jones SC, Budnitz D, Sorbello A, Mehta H. US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions. Pharmacoepidemiol Drug Saf. 2013;22:1099–106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Salas M, Barrionueve E, Fernandez TD, Ruiz A, Andreu I, Torres MJ, et al. Hypersensitivity reactions to fluoroquinolones. Curr Treat Opt Allergy. 2016;3:129–46.

  9. Blanca-Lopez N, Andreu I, Torres Jean MJ. Hypersensitivity reactions to quinolones. Curr. Opin. Allergy Clin. Immunol. 2011;11:285–91.

    Article  CAS  PubMed  Google Scholar 

  10. Dona I, Moreno E, Perez-Sanchez N, Andreu I, DHF D r, Tores MJ. Update on quinolone allergy. Curr. Allergy Asthma Rep. 2017;17:24.

  11. Sachs B, Riege IS, Seebeck J, Beier R, Schichler D, Barger A, et al. Fluroroquinolone associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolone and occurance after first ever use. Drug Saf. 2006;29:1087–100.

    Article  CAS  PubMed  Google Scholar 

  12. Demir S, Gelincik A, Akdeniz N, Aktaş-Çetin E, Olgaç M, Unal D, et al. Usefulness of in vivo and in vitro diagnostic tests in the diagnosis of hypersensitivity reactions to quinolones and in vitro evaluation of cross-reactivity: A comprehensive study including the latest quinolone gemifloxacin. Allergy Asthma Immunol Res. 2017 July;9(4):347–59.

  13. Porebski G, Kwiecien K, Pawica M, Kwitniewski M. Mas-related G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions. Front Immunol. 2018;9:3027.

  14. BD MN, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature. 2015:519, 237–41.

  15. Dona I, Perez-Sanchez N, Sales M, Barrionuevo E, ARS F, DHF d R, et al. Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones. J Allergy Clin Immunol Pract. 2020;8(8):20707–2714. This study determines the diagnostic value of in vivo and in vitro tests in the largest patient cohort. Drug provocation tests serves as the gold standard diagnostic tool whereas skin testing is not a reliable tool. The basophil activation test is useful in detecting safe alternatives.

    Article  Google Scholar 

  16. Blanca-Lopez N, Ariza A, Dona I, Mayorga C, Montanez MI, Garcia-Campos J, et al. Hypersensitivity reactions to fluoroquinolones: analysis of the factors involved. Clin Exp Allergy. 2013;43:560–7.

    Article  CAS  PubMed  Google Scholar 

  17. Blayac JP, Hillaire-Buys D, Pinzani V. Fluoroquinolones and anaphylaxis. Therapie. 1996;51:417–8.

    CAS  PubMed  Google Scholar 

  18. Renaudin JM, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin DA. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the allergy vigilance network from 2002 to 2010. Allergy. 2013;68:929–37.

    Article  CAS  PubMed  Google Scholar 

  19. Aranda A, Mayorga C, ArizaA DI, Rosado A, Blanca-Lopez N, et al. In vitro evaluation of IgE mediated hypersensitivity reactions to quinolones. Allergy. 2011;66:247–54.

    Article  CAS  PubMed  Google Scholar 

  20. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 2007;30:705–13.

    Article  PubMed  Google Scholar 

  21. Ozlek E, Sungur Biteker F, Celik O, Ozlek B, Cil C, Biteker M. Gemifloxacin-induced allergic myocardial infarction: a case report. J Emerg Med. 2019 Jun;56(6):e103–5.

  22. Nunez GI, Marmol MA, BMJ V, Vergara MS, Gonzalez FE, Ariza ER. Kounis syndrome after levofloxacin intake: A clinical report and cross-reactivity study. J Investig Allergol Clin Immunol. 2016;26(5):335–6.

    Article  Google Scholar 

  23. Yılmaz I, Doğan S, Tutar N, Kanbay A, Büyükoğlan H, Demir R. Biphasic anaphylaxis to Gemifloxacin. Asia Pac Allergy. 2012;2:280–2.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Masumoto T, Horino T, Inotani S, Ichii O, Terada Y. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DIHS) caused by levofloxacin in a patient with scleroderma, rheumatoid arthritis and sjogren synderome. Contact Dermat. 2019;80:253–4.

    Article  Google Scholar 

  25. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol. 2008;128(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  26. Scherer K, Bircher AJ. Hypersensitivity reactions to fluoroquinolones. Curr Allergy Asthma Rep. 2005;5(1):15–21.

    Article  CAS  PubMed  Google Scholar 

  27. Demir S, Unal D, Olgac M, Akdeniz N, Aktas-Cetin E, Gelincik A, et al. An unusual dual hypersensitivity reaction to moxifloxacin in a patient. Asia Pac Allergy. 2018;8:e26.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Manfredi M, Severino M, Testi S, Macchia D, Ermini G, Pichler WJ, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol. 2004;113:155–60.

  29. Anti-Infective Drugs Advisors Committee (US). Factive (Gemifloxacin): U.S. Food and Drug administration briefing document. Silver Spring (MD): U.S. Food and Drug Administration. 2003; Mar 4.

  30. Venturini DM, Lobera LT, GMD d P, Blasco SA, Gonzalez MI. In vivo diagnostic tests in adverse reactions to quinolones. J Investig Allergol Clin Immunol. 2011;11:285–91.

    Google Scholar 

  31. Uyttebroek AP, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Moxifloxacin hypersensitivity: uselessness of skin testing. J Allergy Clin Immunol Pract. 2015;3(3):629–30.

    Article  Google Scholar 

  32. Fernandez TD, Ariza A, Palomares F, Montanez MI, Salas M, Martin-Serrano A, et al. Hypersensitivity to quinolones: The expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. Medicine 2016;95:e3679.

  33. Lozano Ayllon M, Gomez Martinez M, Mosquera MR, Laguna Martinez J, Orta Martiartu M, Fernandez de Miguel C. Fixed eruption caused by ciprofloxacin without cross-reactivity to norfloxacin. Allergy. 1995;50(7):598–9.

    Article  CAS  PubMed  Google Scholar 

  34. Nunez Otero V, Limeres Posse J, Carmona IT, Diz Dios P. Efficacy of fluoroquinolones against pathogenic oral bacteria. Mini Rev Med Chem. 2009;9:1147–58.

    Article  CAS  PubMed  Google Scholar 

  35. Davila I, Diez ML, Quirce S, Fraj J, De La Hoz B, Lazaro M. Cross-reactivity between quinolones. Report of three cases. Allergy. 1993;48:388–90.

    Article  CAS  PubMed  Google Scholar 

  36. Gonzalez I, Lobera T, Blasco A, Del Pozo MD. Immediate hypersensitivity to quinolones: Moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol. 2005;15:146–9.

    CAS  PubMed  Google Scholar 

  37. Lobera T, Audicana MT, Alarcon E, Longo N, Navarra B, Munoz D. Allergy to quinolones: low cross-reactivity to levofloxacin. J Investig Allergol Clin Immunol. 2010;20:607–11.

    CAS  PubMed  Google Scholar 

  38. Sanchez-Morillas L, Rojas Perez-Ezquerra P, Reano-Martos M, Laguna-Martinez JJ, Gomez-Tembleque P. Systemic anaphylaxis caused by moxifloxacin. Allergol Immunopathol. 2010;38(4):226–7.

    Article  CAS  Google Scholar 

  39. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clinical and Experimental allergy: Journal of the British Society for Allergy and Clinical Immunology. 2006;36(1):59–69.

    Article  CAS  Google Scholar 

  40. Tokura Y, Seo N, Yagi H, Furukawa F, Takigawa M. Cross-reactivity in murine fluoroquinolone photoallergy: exclusive usage of TCR Vbeta13 by immune T cells that recognize fluoroquinolone-photomodified cells. J Immunol. 1998;160:3719–28.

    Article  CAS  PubMed  Google Scholar 

  41. Rouzaire P, Nosbaum A, Mullet C, Diot N, Dubost R, Bienvenu F, et al. Immediate allergic hypersensitivity to quinolones associates with neuromuscular blocking agent sensitization. J Allergy Clin Immunol Pract. 2013;1(3):273-9e.

    Article  Google Scholar 

  42. Lantner RR. Ciprofloxacin desensitization in a patient with cystic fibrosis. J Allergy Clin Immunol. 1995;96:1001–2.

    Article  CAS  PubMed  Google Scholar 

  43. Benken ST, Nyenhuis SM, Dunne S. Sequential rapid oral desensitization to rifampin and moxifloxacin for the treatment of active mycobacterium tuberculosis. J Allergy Clin Immunol Pract. Jan-Feb 2017;5(1):195-197.

  44. Bircher AJ, Rutishauser M. Oral desensitization of maculopapular exanthema from ciprofloxacin. Allergy 1997;52:1246-124846.

  45. West RM, Smith CJ, Pavitt SH, Butler CC, Howard P, Bates C, et al. ‘Warning: allergic to penicillin’: association between penicillin allergy status in 2.3 million NHS general practice electronic health records, antibiotic prescribing and health outcomes. J Antimicrob Chemother. 2019;74:2075–82.

    Article  CAS  PubMed  Google Scholar 

  46. Firth A, Prathapan P. Azithromycin: The first Broad-spectrum Therapeutic. Eur J Med Chem. 2020 Aug 19;207:112739.

  47. Wong E, Porter JD, Edwards MR, Johnston SL. The role of macrolides in asthma: Current evidence and future directions. Lancet Respir Med. 2014;2:657–70.

    Article  CAS  PubMed  Google Scholar 

  48. Araujo L, Demoly P. Macrolides allergy. Curr Pharma Des. 2008;14:2840–62.

    Article  CAS  Google Scholar 

  49. Macy E, Poon K-Y. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122:778.e1–7.

    Article  Google Scholar 

  50. Orhan F, Karakas T, Cakir M, Akkol N, Bahat E, Sonmez FM, et al. Parental-reported drug allergy in 6- to 9-y-old urban school children. Pediatr Allergy Immunol. 2008, 19:82–5.

  51. Piccorossi A, Liccioli G, Barni S, Sarti L, Giovannini M, Verrotti A. et al, Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care paediatric hospital setting. Ital J Pediatr. 46:5.

  52. VAK T, IFA G, Van Baver HP. Prevalence of drug allergy in Singaporean children. Singapore Med J. 2009;50:1158–61.

    Google Scholar 

  53. Gelincik A, Özşeker ZF, Çolakoğlu B, Dal M, Büyüköztürk S. Hypersensitivity reactions due to antibiotics: the significance of provocation tests in determining alternative antibiotics. Asthma Allergy Immunol. 2013;11:23–31.

    Google Scholar 

  54. Benahmed S, Scaramuzza C, Messaad D, Sahla H, Demoly P. The accuracy of the diagnosis of the suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial. Allergy. 2004;59:1130–3.

    Article  CAS  PubMed  Google Scholar 

  55. Ünal D, Demir S, Gelincik A, Olgaç M, Coşkun R, Çolakoğlu B, et al. Diagnostic value of oral challenge testing in the diagnosis of macrolide hypersensitivity. J Allergy Clin Immunol Pract. 2018;6:521–7. This study shows the low prevalence of cross-reactivity between different macrolide antibiotics and outlines the importance of drug provocation test in diagnosis and determining alternative macrolides.

  56. Saenz de San Pedro B, Gomez A, Quiralte J, Florido JF, Martin E, Hinojoso B. FDE to macrolides. Allergy. 2002;57:55–6.

    Google Scholar 

  57. Seitz CS, Bröcker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr). 2011;39(4):193–9.

    Article  Google Scholar 

  58. Mori F, Barni S, Pucci N, Rossi E, Azzari C, de Martino M, et al. Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy. Ann Allergy Asthma Immunol. 2010;104:417–9.

  59. Pascual C, Crespo JF, Quiralte J, Lopez C, Wheeler G, Martin-Esteban M. In vitro detection of specific IgE antibodies to erythromycin. J Allergy Clin Immunol. 1995;95:668–71.

    Article  CAS  PubMed  Google Scholar 

  60. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol. 2003;112:629–30.

    Article  CAS  PubMed  Google Scholar 

  61. Riley L, Mudd L, Baize T, Herzig R. Cross-sensitivity reaction between tacrolimus and macrolide antibiotics. Bone Marrow Transplant. 2000;25:907–8.

    Article  CAS  PubMed  Google Scholar 

  62. Holmes NE, Hodgkinson M, Dendle C, Korma TM. Report of oral clarithromycin desensitization. Br. J. Clin. Pharmacol. 2008;66:323–4.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Swamy N, Laurie SA, Ruiz-Huidobro E, Khan DA. Successful clarithromycin desensitization in a multiple macrolide-allergic patient. Ann. Allergy Asthma Immunol. 2010;105:489–90.

    Article  PubMed  Google Scholar 

  64. Petitto J, Chervinskiy SK, Scurlock AM, Perry TT, Jones SM, Pesek RD. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. J. Allergy Clin. Immunol. Pract. 2013;1:307–8.

    Article  PubMed  Google Scholar 

  65. Brackett CC, Harleen S, Likelihood BJ. Mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24:856–70.

    Article  CAS  PubMed  Google Scholar 

  66. Falagas ME, Grammatikos AP, Michalopoulos A. Potential old-generation antibiotics to address current need for new antibiotics. Expert Rev Anti Infect Ther, 600. 2008;6:593.

  67. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E, Hennessy S, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628–35.

    Article  CAS  PubMed  Google Scholar 

  68. Bigby M, Jick S, Jick H, Arndt K. Drug induced cutaneous reactions: a report from the Boston Collabrorative Drug Surveillance Program on 15,438 consecutive inpatients 1975 to 1982. JAMA. 1986;256:3358–63.

    Article  CAS  PubMed  Google Scholar 

  69. Saka B, Barro-Traore F, Atadokfede FA, Kobangue L, Niamba PA, Adegbidi H, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52:575–9.

    Article  PubMed  Google Scholar 

  70. Verhagen C, Stalpers L, de Pauw B, Haanen C. Drug-induced skin reactions in patients with acute non-lymphocytic leukemia. Eur J Hematol. 1987;38:225–30.

    Article  CAS  Google Scholar 

  71. Abouraya M, Sacco JC, Kahl BS, Trepanier LA. Evaluation of sulfonamide detoxification pathways in hematologic malignancy patients prior to intermittent trimethoprim-sulfamethoxazole prophylaxis. Br J Clin Pharmacol. 2011;71:566–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity ractions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol. 2010;153:152–6.

    Article  CAS  PubMed  Google Scholar 

  73. Schnyder B, Burkhart C, Schnayder-Frutig K, von Greyerz S, Naisbitt DJ, Pirmohamed M, et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+T cells from allergic individuals. J Immunol. 2000;164:6647–54.

    Article  CAS  PubMed  Google Scholar 

  74. van der Klauw MM, Wilson JH, Stricker BH. Drug-associated anaphylaxis: 20 years of reporting in the Netherlands (1974-1994) and review of the literature. Clin Exp Allergy. 1996;26:1355–63.

    Article  PubMed  Google Scholar 

  75. Arndt PA, Garratty G, Wolf CF, Rivera M. Hemolytic anemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole. Transfus Med. 2011;21:194–8.

    Article  CAS  PubMed  Google Scholar 

  76. Adam J, Pichler WJ. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol. 2011;71:701–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation and management. Hematol Am Soc Hematol Educ Progr. 2009:153–8.

  78. Martin J, Abbott G. Serum sickness like illness and antimicrobials in children. N Z Med J. 1995 Apr 12;108(997):123–4.

  79. Raksha MP, Marfatia YS. Clinical study of cutaneous drug eruptions in 200 patients. Indian J Dermatol Venerol Leprol. 2008;74:80.

    Article  Google Scholar 

  80. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective ReiSCAR study. Br J Dermatol. 2013;169:1071–80.

    Article  CAS  PubMed  Google Scholar 

  81. Sharma V, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents- a 6 year series from Chandigarh. India J Postgr Med. 2001;47:95–9.

    CAS  Google Scholar 

  82. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272–85.

    Article  CAS  PubMed  Google Scholar 

  83. Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57:115–9.

    Article  CAS  PubMed  Google Scholar 

  84. Wang D, Curtis A, Papp AC, Koletar SL, Para MF. Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients. Biomed Cent Med. Genomics. 2012;5:1–9.

    CAS  Google Scholar 

  85. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123:1171–3.

    Article  CAS  PubMed  Google Scholar 

  86. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18:99–107.

    Article  CAS  PubMed  Google Scholar 

  87. Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, et al. Candidate HLA genes for predictiob of co-trimaxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015;25:402–11.

    Article  CAS  PubMed  Google Scholar 

  88. Weiss ME, Bernstein DI, Blessing-Moore J, Cox L, Lang DM, Nicklas RA, et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105:259–273:e78.

    Article  CAS  Google Scholar 

  89. Dibbern DA, Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann Allergy Asthma Immunol. 2008 Feb;100(2):91–100.

  90. Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: Fact and Fiction. J Allergy Clin Immunol Pract. 2019;7:2116–23. This review emphasizes the limited significance of skin testing and the importance of a multistep desensitization or challenge in immediate and non-immediate hypersensitivity reactions due to sulfamethoxazole.

    Article  PubMed  Google Scholar 

  91. Gruchalla RS, Sullivan TJ. Detection of human IgE to sulfamethoxazole by skin testing with sulfamethoxazoyl-poly-L-tyrosine. J Allergy Clin Immunol. 1991;88:784–92.

    Article  CAS  PubMed  Google Scholar 

  92. Ozkaya-Beyazıt E, Beyazit H, Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole induced fixed drug eruption. Contact Dermat. 1999;41:185–9.

    Article  Google Scholar 

  93. Dorn JM, Alpern M, McNulty C, Volchech GW. Sulfonamide drug allergy. Curr. Allergy Asthma Rep. 2018;18:38.

    Article  PubMed  Google Scholar 

  94. Leoung GS, Stanford JF, Giordano MF, Stein A, Torres RA, Giffen CA, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for pneumocystis carinii prophylaxis in human immunodeficiency virus infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis. 2001;184:992–7.

    Article  CAS  PubMed  Google Scholar 

  95. Neuman MG, Malkiewicz IM, Shear NH. A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem. 2000;33:517–24.

    Article  CAS  PubMed  Google Scholar 

  96. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharma Ther. 1981;30(2):239–45.

    Article  CAS  Google Scholar 

  97. Kalish RS, LaPorte A, Wood JA, Johnson KL. Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions. J Allergy clin Immunol 1994;94(3 Pt 1):465-472.

  98. Vilchez-Sanchez F, Loli-Ausejo D, Rodriguez-Mariblanca A, Montserrat-villatoro J, Ramirez E, Domingues-Ortega J, et al. Lymphcye transformation test can be useful for the diagnosis of delayed adverse reactions to sulfonamides. Allergy. 2020;00:1–6. This study indicates that lymphocyte transformation test with its high sensitivity and specificity could be a valuable method in diagnosis of sulphonamide allergy.

  99. Schnyder B, Pichler WJ. Allergy to sulfonamides review. J Allergy Clin Immunol 2013;131:e1-2 257.

  100. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809-820.

  101. Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ. Drug interaction with T-cell receptors density determines degree of cross-reactivity. J Allergy Clin Immunol. 2004;113:519–27.

    Article  CAS  PubMed  Google Scholar 

  102. The joint Task Force on Practice Parameters. Crug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105:259–73.e78.

    Article  Google Scholar 

  103. du Toit G, Reynolds L, Eley B. Introduction of tolerance after a serious trimethoprim sulphamethoxazole reaction in an HIV-infected child. S Afr Med J. 2003;93:358–9.

    PubMed  Google Scholar 

  104. Lin D, Li WK, Rieder MJ. Cotrimaxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev. 2007;18(2):CD005646.

    Google Scholar 

  105. Bonfanti P, Pusterla L, Parazzini F, Libanore M, Cagni AE, Franzetti M, et al. The effectiveness of desensitization versus rechallenge treatment in HIV-positive patients with previous hypersensitivity to TMP-SMX: a randomized multicentric study. C.I.S.A.I. Group. Biomed Pharmacother. 2000;54:45–9.

    Article  CAS  PubMed  Google Scholar 

  106. Straatmann A, Bahia F, Pedral-Sampaio D, Brites C. A randomized pilot trial comparing full versus escalating dose regimens for the desensitization of AIDS patients alleric to sulfonamides. Braz J Infect Dis. 2002;6:276–80.

    Article  PubMed  Google Scholar 

  107. Demoly P, Messaad D, Sahla H, Fabre J, Faucherre V, Andre P, et al. Six-hour trimethoprim-sufamethoxazole-graded challenge in HIV-infected patients. J Allergy clin Immunol. 1998;102:1033-6.

  108. Scherer K, Brockow K, Aberer W, Gooi JHC, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions-an EAACI position paper of the drug allergy interest group. Allergy Eur. J Allergy Clin Immunol. 2013;68:844-52.

  109. Fanning A. Tuberculosis: 6 extrapulmonary disease. CMAJ. 1999;160(11):1597-603.

  110. WHO: Global Tuberculosis Report. Geneva: World Health Organisation; 2019.

  111. World Health Organization. WHO guidelines for treatment of drug susceptible tuberculosis and patient care 2017 update. Genova: World Health Organization. 2017. [Accessed 4 July 2019]. Available from https://www.who.int/tb/publications/2017/dstb_guidance_2017/en/.

  112. Campbell JR, Al-Jahdali H, Bah B, Belo M, Cook VJ, Long R, et al. Safety and efficacy of rifampin or isoniazid among people with mycobacterium tuberculosis infection and living with human immunodeficiency virus or other health conditions: post hoc analysis of 2 randomized trials. Clin Infect Dis. 2020 Aug 12:ciaa1169.

  113. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5:231–49.

    Article  CAS  PubMed  Google Scholar 

  114. Kim SH, Lee BH, Lee KD, Park JS, Kim YS, Jee YK, et al. The prevalnee of adverse drug reations to a short course anti-tuberculosis regimen. Korean J Med. 2007;73:496–50.

    Google Scholar 

  115. Carroll W, Lee M, Chai Y, Hallahan CW, Shaw PA, Min JH, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J tubercul Lung Dise 2012;16:961-966.

  116. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Men-zies D. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7.

    Article  PubMed  Google Scholar 

  117. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J. 1996;9:2026–30.

    Article  CAS  PubMed  Google Scholar 

  118. Köycü-Buhari G, Keren M, Dursun AB, Güler M, Dulkar G, Kalaç N, et al. Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocol. Ann Allergy Asthma Immunol. 2015;115:39–44.

    Article  CAS  Google Scholar 

  119. Jo KW, Kim JS, Kwon HS, Park YE, Kim JY, Hong MJ, et al. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. Respir Med. 2019;158:42–8.

  120. Carneiro-Leão L, Gomes I, Freitas C, Costa E Silva M, Viseu R, Cernadas J. Multiple drug hypersensitivity syndrome to antituberculosis drugs: a case report. J Investig Allergol Clin Immunol. 2020;30(1):70–1.

    Article  PubMed  Google Scholar 

  121. Kim SH, Lee SK, Kim SH, Park HW, Chang YS, et al. Antituberculosis drug-induced hypersensitivity syndrome and its association with human leukocyte antigen. Tuberculosis. 2013;93:270–4.

    Article  CAS  PubMed  Google Scholar 

  122. Saukkonen JJ, Chon DL, Jasmer RM, Scenker S, Jereb JA, Nolan CM, et al. An official STS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006:174, 935–952.

  123. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.

    Article  PubMed  Google Scholar 

  124. Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med J Malaysia. 2007;62:143–6.

    CAS  PubMed  Google Scholar 

  125. Pitch P, Mouzou T, Padonou C, Tchangai-Walla K. Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo. Med Trop (Mars). 2005;65:359–62.

    Google Scholar 

  126. Ribi C, Hauser C. Adverse reactions to pyrazinamide. Allergy. 2002;57:964–5.

    Article  CAS  PubMed  Google Scholar 

  127. Kim SH, Kim SH, Yoon HJ, Shin DH, Park SS, Kim YS, et al. NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug induced maculopapular eruption. Eur J Clin Pharmacol. 2011;67:121–7.

    Article  CAS  PubMed  Google Scholar 

  128. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmezs W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Bavbek S, Yılmaz I, Aydın Ö, Özdemir SK. Pyrazinamide-induced anaphylaxis: diagnosed by skin test and successful desensitization. Int Arch Allergy Immunol. 2012;157:209–12.

    Article  PubMed  Google Scholar 

  130. Kato Y, Sato Y, Nakasu M, Tsuboi R. Immediate type hypersensitivity and late phase reaction occurred consecutively in a patient receiving ethambutol and levofloxacin. Allergy Asthma Clin Immunol. 2018 Apr 3;14:13.

  131. Broz P, Harr T, Hecking C, Grize L, Scherer K, Jaeger KA, et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin and rifampicin. Allergy. 2012;67:647–52.

  132. Buergin S, Scherer K, Hausermann P, et al. Immediate hypersensitivity to rifampicin in 3 patients: Diagnostic procedure and induction of clinical tolerance. Int Arch Allergy Immunol. 2006;140:20–6.

    Article  CAS  PubMed  Google Scholar 

  133. Rodrigues Carvalho S, Silva I, Leiria-Pinto P, Rosado-Pinto J. Rapid oral tolerance induction to isoniazid and pyrazinamide and controlled administration of ethambutol: clinical case. Allergol Immunopathol (Madr). 2009;37:336–8.

    Article  CAS  Google Scholar 

  134. Ban GY, Jeong YJ, Lee SH, Shin SS, Shin YS, Park HS, et al. Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivity to anti-tuberculosis medications. Respir Med. 2019;147:44–50.

    Article  PubMed  Google Scholar 

  135. Allouchery M, Logerot S, Cottin J, Pralong P, Villier C, Said BB, et al. Antituberculosis drug-associated DRESS: a case series. J Allergy Clin Immunol Pract. 2017.

  136. Suzuki Y, Miwa S, Shirai M, Ohba H, Murakami M, Fujita K, et al. Drug lymphocyte stimulation test in the diagnosis of adverse reaction to antituberculosis drugs. Chest. 2008;134:1027–32.

    Article  CAS  PubMed  Google Scholar 

  137. Lehloenya RJ, Todd G, Badri M, Dheda K. Outcomes of reintroducing anti-tuberculosis drugs following cutaneous adverse drug reactions. Int J tuberc Lung Dis. 2011;15:1649–55.

    Article  CAS  PubMed  Google Scholar 

  138. Nagarajan S, Whitaker P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr Opin Allergy Clin Immunol. 2018;18:000–0.

  139. Lehloenya RJ, Todd G, Wallace J, Ngwanya MR, Muloiwa R, Dheda K. Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol. 2016 Jul;175(1):150–6.

  140. Cernadas JR, Santos N, Pinto C, Mota PC, Castells M. Hypersensitivity reaction and tolerance induction to ethambutol. Case Rep Med. 2013;2013:208797.

    Article  PubMed  PubMed Central  Google Scholar 

  141. BYH T, Lucas M, Kang HR, Chang YS, Li HP, Tang MM, et al. Drug hypersensitivity reactions in Asia: regional issues and challenges. Asia Pac Allergy. 2020 Jan;10(1):e8.

  142. Roy M, Ahmad S, Roy AK. Successful rapid oral desensitization for dual hypersensitivity to isoniazid and rifampin while treating central nervous system tuberculosis. J Community Hosp Intern Med Perspect. 2018;8(6):345–8.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Kim JH, Kim HB, Kim BS, Hong SJ. Rapid oral desensitization to isoniazid, rifampin and ethambutol. Allergy. 2003;58:540–1.

    Article  PubMed  Google Scholar 

  144. Siripassorn K, Ruxrungtham K, Manosuthi W. Successful drug desensitization in patients with delayedtype allergic reactions to anti-tuberculosis drugs. Int J Infect Dis. 2018;68:61–8.

    Article  CAS  PubMed  Google Scholar 

  145. Sanmukhani J, Shah V, Baxi S, Tripathi C. Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: a case report. Br J Clin Pharmacol. 2010;69(6):703–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Garcia-Rubio I, Martinez-Cocera C, Magadan SS, Rodriguez-Jimenez B, Vazquez-Cortes S. Hypersensitivity reactions to metronidazole. Allergol et Immunopathol. 2006;34(2):70–2.

    Article  Google Scholar 

  147. Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018;73:265–79.

    Article  CAS  PubMed  Google Scholar 

  148. Ozkaya E. Changing trends in inducer drugs of fixed drug eruption: 1 20-year cross-sectional study from Turkey. J Dtsch Dermatol Ges. 2018;16(4):474–6.

    Article  PubMed  Google Scholar 

  149. Asensio Sanchez T, Davila I, Moreno E, Laffond E, Macias E, Ruiz A, et al. Anaphylaxis due to metronidazole with positive skin prick test. J Investig Allergol Clim Immunol. 2008;18(2):138–9.

  150. Kumar N, Sundriyal D, Walia M, Trisal D, et al. BMJ Case Rep. 2013;2013:325–6.

    Google Scholar 

  151. Mazumdar G, Stevens-Johnson SK. Syndrome following use of metronidazole in a dental patient. Indian J Pharmacol. 2014;46(1):121–2.

    Article  PubMed  PubMed Central  Google Scholar 

  152. VanCleave HZ, Snachez AC, Lieberman JA, Ellenburg JT, Mabry WA. Probable metronidazole induced serum sciness-like reaction in a pediatric patient. J Clin Pharm Ther. 2016;41(6):736–8.

    Article  Google Scholar 

  153. Anibarro B, Fontela JL. Immediate rhinoconjunctivitis induced by metamizole and metronidazole. Ann Allergy Asthma Immunol. 1997;78(4):345–6.

    Article  CAS  PubMed  Google Scholar 

  154. Beyaz S, Akdeniz N, Yılmaz A, Demir S, Öztop N, Çolakoğlu B, et al. Diagnostic workup including CD203c-based basophil activation test in immedate hypersensitivity due to metronidzole and ornidazole and evaluation of cross-reactivity in between. Allergy. 2020;00:1–11.

    Google Scholar 

  155. Bavbek S, Yılmaz I, Sözener ZÇ. Fixed drug eruption caused by ornidazole and fluconazole but not isoconazole, itraconazole, ketoconazole and metronidazole. J Dermatol 2013 Feb;40(2):134-5.

  156. Gupt S, Mahendra A, Gupta S, Kaur S. Multiple fixed drug eruption caused by ornidazole. Dermititis Nov-Dec 2010;21(6):330-3.

  157. Kanwar AJ, Sharma R, Rajagopalan M, Kaur S. Fixed drug eruption due to tinidazole with cross-reactivity with metronidazole. Dermatologica 1990;180(4):277.

  158. Mishra D, Mobashir M, Zaheer MS. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 1990;29(10):740.

  159. Sanchez-Borges M, Gonzalez-Aveledo LA. Fixed drug eruptions induced by cross-reactive imidazoles. Allergol Immunopsthol (Madr) 2011;39(i):246-247.

  160. Mithari HS, Gole PV, Kharkar VD, Mahajan SA. Generalized bullous fixed drug eruption to fluconazole; with cross-reactivity to tinidaole. Indian J Dermatol. 2019;64(4):335–7.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol. 2008;198:370-e371–7. https://doi.org/10.1016/j.ajog.2007.10.795.

    Article  CAS  Google Scholar 

  162. Gilbert DN, Leggett JE. In: Mendell D, Mendell GL, Bennett JE, Dolin R, editors. Aminoglycosides. In Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 7th edition. Churchill Livingstone Elsevier: Philadelphia; 2010. p. 359–84.

    Google Scholar 

  163. Serio AW, Keepers T, Andrews L, Krause KM. Aminoglycoside revival: Review of a historically important class of antimicrobials undergoing rejuvenation. EcoSal Plus. 2018;8.

  164. de Padua CA, Uter W, Schnuch A. Contact allergy to topical drugs: prevalence in a clinical setting and estimation of frequency at the population level. Pharmacoepidemiol Drug Saf. 2007;16:377–84.

    Article  PubMed  CAS  Google Scholar 

  165. Durocher LP. Reaction allerggique aux medicaments topiques. CMA J. 1978;118:162–4.

    CAS  Google Scholar 

  166. Macy E, Romano A, Khan D. Practical management of antibiotic hypersensitivity in 2017. J. Allergy Clin. Immunol. Pract. 2017;5:577–86.

    Article  PubMed  Google Scholar 

  167. Childs-Kean LM, Shaeer KM, Gupta SV, Cho CJ. Aminoglycoside allergic reactions. Pharmacy 2019;7:124.

  168. Romano A, Viola M, Di Fonso M, Rosaria Perrone M, Gaeta F, Andriolo M. Anaphylaxis to streptomycin. Allergy. 2002;57:1087–8.

    Article  CAS  PubMed  Google Scholar 

  169. Schulze S, Wollina U. Gentamicin-induced anaphylaxis. Allergy. 2003;58:88.

    Article  CAS  PubMed  Google Scholar 

  170. Chao YK, Shyur SD, Wu CY, Wang CY. Childhood serum sickness: A case report. J. Microbiol. Immunol. Infect. 2001;34:220–3.

    CAS  PubMed  Google Scholar 

  171. Bensaid B, Rozieres A, Nosbaum A, Nicolas J, Berard F. Amikacin induced drug reaction with eosinophilia and systemic symptoms syndrome: delayed skin test and ELISPOT assay results allow the identification of the culprit drug. J Allergy Clin Immunol. 2012;130:1413–4.

    Article  CAS  PubMed  Google Scholar 

  172. Haeberle M, Wittner B. Is gentamicin-loaded bone cement a risk for developing systemic allergic dermatitis? Contact Dermat. 2009;60:176–7.

    Article  Google Scholar 

  173. Paniagua MJ, Garcia-Ortega P, Tella R, Gaig P, Richart C. Systemic contact dermatitis to gentamicin. Allergy. 2002;57:1086–7.

    Article  CAS  PubMed  Google Scholar 

  174. Sanchez-Perez J, Lopez MP, De Vega Haro JM, García-Díez A. Allergic contact dermatitis from gentamicin eye drops, with cross-reactivity to kanamycin, but not neomycin. Contact Dermat. 2001;44:54.

    Article  CAS  Google Scholar 

  175. Guin JD, Phillips D. Erythodema from systemic contact dermatitis: A complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis. 1989;43:564–7.

    CAS  PubMed  Google Scholar 

  176. Binenbaum G, Bruno CJ, Forbes BJ, Snyder M, Mollen TJ, Schmidt B, et al. Periocular ulcerative dermatitis associated with gentamicin ointment prophylaxis in newborns. J. Pediatr. 2010;156:320–1.

  177. Castellazzi ML, Esposito S, Claut LE, Daccò V, Colombo C. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in two young children: The importance of an early diagnosis. Ital. J. Pediatr. 2018;44:93.

  178. Connolly M, McAdoo J, Bourke JF. Gentamicin-induced anaphylaxis. Ir. J. Med. Sci. 2007;176:317–318.

  179. Henao CMG, Morales CIH, Villa RC, Henao AMC. Gentamicin induced anaphylaxis, a case report. World Allergy Organ. J. 2015;8:A269.

  180. Kendigelen P, Baktir M, Sucu A, Kaya G. Anaphylaxis after administration of amikacin containing sodium metabisulfite in a premature newborn. Arch. Argent. Pediatr. 2016;114:e195–8.

    PubMed  Google Scholar 

  181. Christiansen IS, Pedersen P, Krøigaard M, Mosbech H, Garvey LH. Anaphylaxis to intravenous gentamicin with suspected sensitization through gentamicin-loaded bone cement. J. Allergy Clin. Immunol. Pract. 2016;4:1258–9.

    Article  PubMed  Google Scholar 

  182. Ting JY. Ocular tobramycin-induced bronchospasm in an adult without asthma or atopy. Can. J. Ophthalmol. 2007;42:883–4.

    Article  PubMed  Google Scholar 

  183. Santos RP, Awa E, Anbar RD. Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: A case report. BMC Pediatr. 2007;7:11.

  184. Schretlen-Doherty JS, Troutman WG. Tobramycin-induced hypersensitivity reaction. Ann. Pharmacother. 1995;29:704–706.

  185. De Groot AC, Malbach HI. Frequency of sensitization to common allergens: comparison between Europe and the USA. Contact Derm. 2010;62:325–9.

    Article  Google Scholar 

  186. de Padua CAM, Schnuch A, Lessmann H, Phalberg A, Uter W. Contact allergy to neomycin sulphate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf. 2005;14:725–33.

  187. Vervloet D, Pradal M, Birbaun J, Koeppel MC. Drug allergy. Paris: Editions de Conde. 2007.

  188. Likura M, Yamaguchi M, Hirai K, Suenaga A, Fujiwara T, Fujii T, et al. Case report: streptomycin-induced anaphylacitic shock during oocyte retrieval procedures for in vitro fertilization. J Allergy Clin Immunol. 2002;109:571–2.

    Article  Google Scholar 

  189. Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: epidemiology, responsible allergens and management. J Am Acad Dermatol 2008. 58:1–21.

  190. Yoo JY, Al Naami M, Markowitz O, Hadi SM. Allergic contact dermatitis: patch testing results at Mount Sinai Medical Center. Skinmed. 2010;8:257–60.

    PubMed  Google Scholar 

  191. Thomas B, Kulichova D, Wolf R, Summer B, Mahler V, Thomas P. High frequency of contact allergy to implant and bone cement components, in particular gentamicin, in cemented arthroplasty with complications: usefulness of late patch test reading. Contact Dermat. 2015;73:343–9.

    Article  CAS  Google Scholar 

  192. Anibarro B, Seoane FJ. Immediate allergic reaction due to Neomycin. J Investig Allergol Clin Immunol. 2009;19(1):64–79.

    CAS  PubMed  Google Scholar 

  193. Schorr WF, Ridgway HB. Tobramycin-neomycin cross-sensitivity. Contact Dermat. 1977;3:133–7.

    Article  CAS  Google Scholar 

  194. Chung CW, Carson TR. Cross-sensitivity of common aminoglycoside antibiotics. Arch. Dermatol. 1976;112:1101–7.

    Article  CAS  PubMed  Google Scholar 

  195. Kimura M, Kawada A. Contact sensitivity induced by neomycin with cross-sensitivity to other aminoglycoside antibiotics. Contact Dermat. 1998;39:148–50.

    Article  CAS  Google Scholar 

  196. Romano A, Caubet JC. Antibiotic allergies in children and adults: From clinical symptoms to skin testing diagnosis. J. Allergy Clin. Immunol. Pract. 2014;2:3–12.

    Article  PubMed  Google Scholar 

  197. Lippo J, Lammintausta K. Positive patch test reactions to gentamicin show sensitization to aminoglycosides from topical therapies, bone cements, and from systemic medication. Contact Dermat. 2008;59:268–72.

    Article  Google Scholar 

  198. Spigarelli MG, Hurwitz ME, Nasr SZ. Hypersensitivity to inhaled Tobi following reaction to gentamicin. Pediatr. Pulmonol. 2002;33:311–4.

    Article  PubMed  Google Scholar 

  199. Earl HS, Sullivan TJ. Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J. Allergy Clin. Immunol. 1987;79:477–83.

    Article  CAS  PubMed  Google Scholar 

  200. Whitaker P, Shaw N, Gooi J, Etherington C, Conway S, Peckham D. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J. Cyst. Fibros. 2011;10:282–5.

    Article  CAS  PubMed  Google Scholar 

  201. Chaudhuri A, Martinez-Martin P, Kennedy PG, Seaton RA, Portegies P, Bojar M, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol. 2008;15:649–59.

    Article  CAS  PubMed  Google Scholar 

  202. Binda E, Marinelli F, Marcone GL. Old and new glycopeptide antibiotics: action and resistance. Antibiotics. 2014;3:572–94.

    Article  PubMed  PubMed Central  Google Scholar 

  203. Sivagnanam S, Deleu D. Red man syndrome. Critical Care. 2003;7:119.

    Article  PubMed  Google Scholar 

  204. Harper NJ, Cook TM, Garcez T, et al. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaesth. 2018;121:159–71.

    Article  CAS  PubMed  Google Scholar 

  205. Hall V, Wong M, Munsif M, Stevenson BR, Elliott K, Lucas M, et al. Antimicrobial anaphylaxis: the changing face of severe antimicrobial allergy. J Antimicrob Chemother. 2020;75:229–35.

    CAS  PubMed  Google Scholar 

  206. Kang DY, Yun J, Lee SY, Koh YI, Sim DW, Kim S, et al. A nationwide study of severe cutaneous adverse reactions based on the multicenter registry in Korea. J Allergy Clin Immunol Pract. 2020 Sep;19:s2213–2198(20)30958–2.

  207. Trubiano JA, Aung AK, Nguyen M, Fehily SR, Graudins L, Cleland H, et al. A comparative analysis between antibiotic- and nonantibiotic-associated delayed cutaneous adverse drug reactions. J Allergy Clin Immunol Pract. 2016;4:1187–93.

    Article  PubMed  Google Scholar 

  208. Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother. 1997;39:371–81.

    Article  CAS  PubMed  Google Scholar 

  209. De Luca JF, Holmes NE, Trubiano JA. Adverse reactions to vancomycin and cross-reactivity with other antibiotics. Curr Opin Allergy Clin Immunol. 2020;20:352–61.

    Article  PubMed  CAS  Google Scholar 

  210. Navines-Ferrer A, Serrano-Candelas E, Lafuente A, Munoz-Cano R, Martin M, Gastaminza G. MRGPRX2- mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018;8:11628.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  211. Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA. HLA-A 32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. et al, 2019;144:183–92.

  212. Arroyo-Mercado F, Khudyakov A, Chawla SG, Cantres-Fonseca O, IM MF. Red man syndrome with oral vancomycin: a case report. Am J Med Case Rep. 2019;7:16–7.

    Article  PubMed  PubMed Central  Google Scholar 

  213. Domis MJ, Moritz ML. Red man syndrome following intraperitoneal vancomycin in a child with peritonitis. Front Pediatr. 2014;2:55.

    Article  PubMed  PubMed Central  Google Scholar 

  214. Nagahama Y, Vanbeek MJ, Greenlee JD. Red man syndrome caused by vancomycin powder. J Clin Neurosci. 2018, 50:149–50.

  215. Minhas JS, Wickner PG, Long AA, Banerji A, Blumentahal KG. Immune-mediated reactions to vancomycin: A systematic case review and analysis. Ann Allergy, Asthma Immunol. 2016;116:544–53.

    Article  CAS  Google Scholar 

  216. Levy JH, Marty AT. Vancomycin anaphylaxis in a patient with vancomycin-induced red man syndrome. Am J Ther. 2000;7:319.

    Article  Google Scholar 

  217. Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth. 1998;80:26.

    Article  CAS  PubMed  Google Scholar 

  218. Bernedo N, Gonzalez I, Gastaminza G, Audicana M, Fernandez E, Munoz D. Positive patch test in vancomycin allergy. Contact Dermat. 2001;45:43.

    Article  CAS  Google Scholar 

  219. Harper V, Nasser SM. Teicoplanin-induced immediate and delayed hypersensitivity reactions. Ann Allergy Asthma Immunol. 2020 Aug;125(2):223–6.

  220. Crespo J, Lainez-Nuez A, Cuevas-Bravo C, Tornero P, Mateos-Mayo A, Rojas-Pérez-Ezquerra P, et al. Acute generalized exanthematous pustulosis due to teicoplanin. J Investig Allergol Clin Immunol. 2020;30(4):303–4.

  221. Tran NP, Katcher J, Rohman E, Hall MF, Michael CF, Miyairi I, et al. Vancomycin hypersensitivity diagnosed by lymphocyte blast transformation. Case Rep Pediatr. 2011;2011:562620.

  222. Kim BK, Kim JH, Sohn KH, Kim JY, Chang YS, Kim SH. Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors. Korean J Intern Med. 2019;35:714–22.

    Article  PubMed  PubMed Central  Google Scholar 

  223. Hsiao SH, Chou CH, Lin WL, Lee EJ, Liao LH, Chang HJ, et al. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J Clin Pharmacy Therap. 2012;37:296–300.

    Article  CAS  Google Scholar 

  224. Macias E, Moreno E, Davila I, et al. Reaction to teicoplanin with tolerance to vancomycin. J Investig Allergol Clin Immunol. 2008;18:71–2.

    CAS  PubMed  Google Scholar 

  225. de Vries E, van Weel-Sipman MH, Vossen JM. A four-year-old child with teicoplanin allergy but no evidence of cross-reaction with vancomycin. Pediatr Infect Disease J. 1994;13:167.

  226. Miyazu D, Kodama N, Yamashita D, Tanaka H, Inoue S, Imakyure O, et al. DRESS syndrome caused by cross reactivity between vancomycin and subsequent teicoplanin administration: a case report. Am J Case Rep. 2016;17:625–31.

    Article  PubMed  PubMed Central  Google Scholar 

  227. Yang LP, Zhang AL, Wang DD, Kee HX, Cheng Q, Wang C. Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. J Clin Pharmacy Therap. 2014;39:442–5.

    Article  CAS  Google Scholar 

  228. Sahai J, Healy DP, Garris R, Berry A, Polk RE. Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis. 1989;160:876–81.

    Article  CAS  PubMed  Google Scholar 

  229. Chopra N, Oppenheimer J, Derimanov GS, Fine PL. Vancomycin anaphylaxis and successful desensitization in a patient with end stage renal disease on hemodialysis by maintaining steady antibiotic levels. Ann Allergy Asthma Immunol. 2000;84:633–5.

    Article  CAS  PubMed  Google Scholar 

  230. Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother. 2001;35:1458–64.

    Article  CAS  PubMed  Google Scholar 

  231. Mahabir S, Lim RY, Fitzpatrick F, Magee C, Keogan M. Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient. World Allergy Organ J. 2013 Sep 30;6(1):16.

  232. Vidal C, Iglesias A, Saez A, Rodriguez M. Hipersensitivity to clindamycin. Ann Pharmacother. 1991;25:317.

    CAS  Google Scholar 

  233. Seitz CS, Bröcker EB, Trautmann A. Allergy diagnostic testing in clindamycin-induced skin reactions. Int Arch Allergy Immunol. 2009;149:246–50.

    Article  CAS  PubMed  Google Scholar 

  234. Bulloch MN, Baccas JT, Arnold S. Clindamycin-induced hypersensitivity reaction. Infection. 2016;44:357–9.

    Article  PubMed  Google Scholar 

  235. Yang Y, Chen S, Yang F, Zhang L, Alterovitz G, Zhu H, et al. HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions. The Pharmacogenomics Journal. 2016;00:1–5.

    Google Scholar 

  236. Jourdan A, Sangha B, Kim E, Nawaz S, Malik V, Vij R, et al. Antibiotic hypersensitivity and adverse reactions: management and implications in clinical practice. Allergy Asthma Clin Immunol. 2020;16:6.

    Article  PubMed  PubMed Central  Google Scholar 

  237. Mazur N, Greenberger PA, Regalado J. Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol. 1999;82:443–5.

    Article  CAS  PubMed  Google Scholar 

  238. Liang EH, Chen LH, Macy E. Adverse reactions associated with penicillins, carbapenems, monobactams, and clindamycin: A retrospective population-based study. J Allergy Clin Immunol Prac. 2020 Apr;8(4):1302–1313.e2.

  239. Grinlington L, Choo S, Cranswick N, Gwee A. Non beta-lactam antibiotic hypersensitivity reactions. Pediatrics. 2020;145:1–10.

    Article  Google Scholar 

  240. Sánchez-Borges M, Thong B, Blanca M, Chiaverini Ensina LF, González-Díaz S, Greenberger PA, et al. Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. WAO Journal. 2013;6:18.

    PubMed  PubMed Central  Google Scholar 

  241. Ebo DG, Mertens C, Braes M, Mennes I, Bridts CH, Sabato V. Clindamycin anaphylaxis confirmed by in vivo and in vitro testing. J Allergy Clin Immunol Pract. 2019 Jan;7(1):331–3.

  242. Vílchez-Sánchez F, Domínguez-Ortega J, Muñoz MG, Loli-Ausejo D, Heredia-Revuelto R, Fiandor Román A, et al. Two case reports of delayed-allergic reactions to clindamycin confirmed with a positive lymphocyte transformation test. Eur Ann Allergy Clin Immunol. 2020;52:91–3.

    Article  PubMed  Google Scholar 

  243. Morales-Cabeza C, Caralli Bonett ME, Micozzi S, Rodríguez MS, Rojas-Pérez-Ezquerra P, de Barrio Fernández M. SDRIFE-like reaction induced by an intradermal skin test with clindamycin: A case report. J Allergy Clin Immunol Pract. Nov-Dec 2015;3(6):976–7.

  244. Alniemi DT, Wetter DA, Bridges AG, el-Azhary RA, MDP D, Camilleri MJ, et al. Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013. Int J Dermatol. 2017 Apr;56(4):405–14.

  245. Tian D, Mohan RJ, Stallings G. Drug rash with eosinophilia and systemic symptoms syndrome associated with clindamycin. Am J Med. 2010 Nov;123(11):e7–8.

  246. Nakamura Y, Wakamatsu K, Muto M. Drug-induced hypersensitivity syndrome induced by clindamycin. Acta Derm-Venereol. 2013 Jan;93(1):83–4.

  247. Karakayalı B, Yazar AS, Çakir D, Cetemen A, Kariminikoo M, Deliloglu B, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome associated with cefotaxime and clindamycin use in a 6 year-old boy: a case report. Pan Afr Med J. 2017;28:218.

  248. Quidley AM, Bookstaver PB, Gainey AB, Gainey MD. Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Pharmacotherapy. 2012;32(12):e387–92.

    Article  Google Scholar 

  249. Romita P, Ettorre G, Corazza M, Borghi A, Foti C. Allergic contact dermatitis caused by clindamycin mimicking ‘retinoid flare’. Contact Dermat, 2017;77:171–1192.

  250. Peter Kim P, Younan N, MT CFRANZCO. Hypersensitivity reaction to intravitreal clindamycin therapy. Clin Experiment Ophthalmol. 2002, 30:147–8.

  251. Paradis N, Marois L, Paradis L, Graham F, Bégin P, Roches AD. Anaphylaxis to clindamycin following cutaneous exposure. Allergy Asthma Clin Immunol. 2020;16:51.

  252. Chiou CS, Lin SM, Lin SP, Chang WG, Chan KH, Ting CK. Clindamycin-induced anaphylactic shock during general anesthesia. J Chin Med Assoc. 2006;69:549–51.

    Article  PubMed  Google Scholar 

  253. Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI drug allergy interest group position paper. Allergy. 2013;68:702–12.

    Article  CAS  PubMed  Google Scholar 

  254. Kuyucu S, Mori F, Atanaskovic-Markovic M, Caubet JC, Terreehorst I, Gomes E, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: An extensive review. Pediatr Allergy Immunol. 2014;25:534–43.

    PubMed  Google Scholar 

  255. Papakonstantinou E, Müller S, Röhrbein JH, Wieczorek D, Kapp A, Jakob T, et al. Generalized reactions during skin testing with clindamycin in drug hypersensitivity: a report of 3 cases and review of the literature. Contact Dermat. 2018 Apr;78(4):274–80.

  256. Notman MJ, Phillips EJ, Knowles SR, Weber EA, Shear NH. Clindamycin skin testing has limited diagnostic potential. Contact Dermat. 2005;53:335–8.

    Article  Google Scholar 

  257. Pereira N, Canelas MM, Brites MM SF, Gonçalo M. Value of patch tests in clindamycin-related drug eruptions. Contact Dermat. 2011 Oct;65:202–7.

  258. Lammintausta K, Tokola R, Kalimo K. Cutaneous adverse reactions to clindamycin: results of skin tests and oral exposure. Br J Dermatol. 2002;146:643–8.

    Article  CAS  PubMed  Google Scholar 

  259. Esty B, Minnicozzi S, Chu EC, Broyles AD, CSK Y. Successful rapid oral clindamycin desensitization in a pediatric patient. J Allergy Clin Immunol Pract. Nov-Dec 2018;6(6):2141–2.

  260. Clindamycin desensitization in an AIDS patient. AIDS. 1995;9:1201–2.

  261. Sande MA, Mendell GL. XI section, chemotherapy of microbial diseases, antimicrobial agents: tetracyclines, chloramphenicol, erythromycin and miscellaneous antibacterial agents. In: Alfred Goodman G, Rall TW, Nies AS, Palmer T, editors. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. 8th edition. Pergamon Press Inc: Oxford. ISBN 0-08-040296-8.

  262. Nelson M, Ismail M. The antibiotic and nonantibiotic tetracyclines. Comp. Med. Chem. 2007;7:742–75.

    Google Scholar 

  263. Maciag MC, Ward SL, O'Connell AE, Broyles AD. Hypersensitivity to tetracyclines: Skin testing, graded challenge, and desensitization regimens. Ann Allergy Asthma Immunol. 2020 Jun;124(6):589–93.

  264. Jourdan A, Sangha B, Kim E, Nawaz S, Malik V, Vij R, et al. Antibiotic hypersensitivity and adverse reactions: management and implications in clinical practice. Allergy Asthma Clin Immunol. 2020 Jan 21;16:6.

  265. Hamilton LA, Guarascio AJ. Tetracycline allergy. Pharmacy. 2019;7:104.

    Article  PubMed Central  Google Scholar 

  266. Ogita A, Takada K, Kawana S. Case of anaphylaxis due to tetracycline hydrochloride. J. Dermatol. 2011;38:597–9.

    Article  PubMed  Google Scholar 

  267. Steinbruegge JM, Judson FN. Type 1 allergic reaction to orally administered tetracycline hydrochloride. Sex. Transm. Dis. 1980;7:193–4.

    Article  CAS  PubMed  Google Scholar 

  268. Barnett CF Jr. Anaphylactoid reaction to orally administered tetracycline. South. Med. J. 1967, 60:963.

  269. Lau BL, Mutyala D, Dhaliwal D. A case report of doxycycline-induced Stevens-Johnson syndrome. Cornea. 2011;30:595–7.

    Article  PubMed  Google Scholar 

  270. Elkayam O, Yaron M, Caspi D. Minocycline-induced autoimmune syndromes: An overview. Semin. Arthritis Rheum. 1999;28:392–7.

    Article  CAS  PubMed  Google Scholar 

  271. Malakar S, Dhar S, Shah Malakar R. Is serum sickness an uncommon adverse effect of minocycline treatment? Arch. Dermatol. 2001;137:100–1.

    CAS  PubMed  Google Scholar 

  272. Clark AK, Shi VY, Sivamani RK. Unique urticarial presentation of minocycline-induced lupus erythematosus. Dermatol. Online J. 2017 Aug 15;23(8):13030/qt6w86q8v4.

  273. Maubec E, Wolkenstein P, Loriot MA, Wechsler J, Mulot C, Beaune P, et al. Minocycline-induced DRESS: Evidence for accumulation of the culprit drug. Dermatology. 2008;216:200–4.

    Article  CAS  PubMed  Google Scholar 

  274. MacNeil M, Haase DA, Tremaine R, Marrie T. Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: A severe adverse reaction to minocycline. J. Am. Acad. Dermatol. 1997;36:347–50.

    Article  CAS  PubMed  Google Scholar 

  275. Fiumara NJ, Yaqub M. Pigmented penile lesions (fixed drug eruptions) associated with tetracycline therapy for sexually transmitted diseases. Sex. Transm. Dis. 1981;8:23–5.

    Article  CAS  PubMed  Google Scholar 

  276. Dodds PR, Chi T. Balanitis as a fixed drug eruption to tetracyclines. J. Urol. 1985;133:1044–5.

    Article  CAS  PubMed  Google Scholar 

  277. Yap LM, Foley PA, Crouch RB, Baker CS. Drug-induced solar urticaria due to tetracycline. Australas. J Dermatol. 2000;41:181–4.

    Article  CAS  PubMed  Google Scholar 

  278. Shimizu Y, Shimao S. A case of minocycline-induced fixed drug eruption. J Dermatol. 1977;4:73–6.

    Article  CAS  PubMed  Google Scholar 

  279. Jang JW, Bae YJ, Kim YG, Jin YJ, Park KS, Cho YS, et al. A case of anaphylaxis to oral minocycline. J Korean Med Sc. 2010;25:1231–3.

    Article  Google Scholar 

  280. Okano M, Imai S. Anaphylactoid symptoms due to oral minocycline. Acta Derm Venereol. 1996;76:164.

  281. Von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31:535–6.

    Article  PubMed  Google Scholar 

  282. Oddo M, Liaude L, Lepori M, Broccard AF, Schaller MD. Relapsing acute respiratory failure induced by minocycline. Chest. 2003;123:2146–8.

    Article  PubMed  Google Scholar 

  283. Toyoshima M, Sato A, Hayakawa H, Taniguchi M, Imokawa S, Chida K. A clinical study of minocycline-induced pneumonitis. Intern Med. 1996;35:176–9.

    Article  CAS  PubMed  Google Scholar 

  284. Raeder JC. Anaphylactoid reactions caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. Drug Intell Clin Pharm. 1984;18:481–2.

    CAS  PubMed  Google Scholar 

  285. Deluze RA, Girard JP. An unusual case of allergy to doxycycline. Allergol et Immunopathol. 1992;20:215–6.

    CAS  Google Scholar 

  286. Gul U, Gonul M, Soylu S, Kaya I. Doxycycline-induced fixed drug eruption. J Dermatol Treat. 2008;19:126–7.

    Article  Google Scholar 

  287. Cac NN, Messingham MJ, Sniezek PJ, Walling HW. Stevens-Johnson syndrome induced by doxycycline. Cutis. 2007;79:119–22.

    PubMed  Google Scholar 

  288. Chan HL, Wong SN, Lo FL. Tetracycline-induced fixed drug eruptions: Influence of dose and structure of tetracyclines. J Am Acad Dermatol. 1985;13:302–4.

    Article  CAS  PubMed  Google Scholar 

  289. Correia O, Delgado L, Polónia J. Genital fixed drug eruption: Cross-reactivity between doxycycline and minocycline. Clin Exp Dermatol. 1999;24:137.

    Article  CAS  PubMed  Google Scholar 

  290. Bargman H. Lack of cross-sensitivity between tetracycline, doxycycline, and minocycline with regard to fixed drug sensitivity to tetracycline. J Am Acad Dematol. 1984;11:900–2.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

    Aslı Gelincik MD & Semra Demir MD

Authors
  1. Aslı Gelincik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Semra Demir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aslı Gelincik MD.

Ethics declarations

Conflict of Interest

Asli Gelinick declares no competing interests. Semra Demir declares no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Drug Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gelincik, A., Demir, S. Hypersensitivity Reactions to Non-Beta Lactam Antibiotics. Curr Treat Options Allergy 8, 161–193 (2021). https://doi.org/10.1007/s40521-021-00293-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40521-021-00293-z

Keywords

Search

Navigation